We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Wright Medical announced a reimbursement "J" code has been assigned
for the company's GRAFTJACKET Ulcer Repair Matrix, a treatment for chronic wounds
often associated with diabetes.
The first fenestrated endograft for the treatment of abdominal aortic aneurysm
(AAA) in Cook's pilot study of advanced endovascular treatments for this life-threatening
condition has been implanted.
Devax announced that enrollment has been completed in the AXXESS PLUS clinical
study for the company's AXXESS Drug Eluting Bifurcation Stent System -- a multi-component
stent delivery system comprising self-expanding Nitinol stents specifically
engineered for the treatment of coronary and vascular bifurcation lesions.
RetinaPharma announced it received 510(k) FDA clearance to market its TonoPach
device that enables more accurate intra-ocular pressure (IOP) determinations
in patients.
Chindex International announced an exclusive, multiyear
distribution agreement for the People's Republic of China with Intuitive Surgical,
the innovator and market leader in surgical robotics.
BioCardia and Symphony Medical announced a mutually exclusive agreement for
development and commercialization of a combination product that combines Symphony
Medical's biotherapeutic technology and BioCardia device delivery technology
for the treatment of cardiac conduction disorders.
Conor Medsystems announced that the underwriters of the company's recent initial
public offering of its common stock have exercised in full their over-allotment
option to purchase an additional 900,000 shares of the company's common stock
at a price of $13 per share, before deducting underwriting discounts and commissions.
A new computer-aided detection (CAD) system can help radiologists detect polyps
in colons that contain contrast-enhanced fluid, says a new study that appears
in the January issue of the American Journal of Roentgenology.
Infectech announced it filed with the FDA to begin the production, marketing
and commercializing of its biophasic system devices intended for medical purposes
to cultivate and identify certain pathogenic microorganisms.
Ten patients with complete motor and sensory spinal cord injury were implanted
with an experimental device designed to regenerate nerve fibers, promoting some
degree of functional recovery.